Review of Active Surveillance in Underrepresented and High-Risk Populations: Feasibility and Safety

Curr Urol Rep. 2023 Jul;24(7):307-315. doi: 10.1007/s11934-023-01158-5. Epub 2023 Mar 30.

Abstract

Purpose of review: The purpose of this review is to investigate the current use and effectiveness of active surveillance (AS) for clinical low-risk prostate cancer (PCa) in men considered to be "high-risk" based on the factors of race, genetics, healthcare access, and socioeconomic status.

Recent findings: Advances in molecular biomarkers and imaging have improved the detection, risk stratification, and treatment of PCa. Still, overdiagnosis and overtreatment of indolent disease remain a concern. AS is therefore the preferred option for clinical low-risk disease. Yet, because of the variability in PCa presentation based on the aforementioned environmental and genetic factors, the question remains: Is active surveillance a safe option for everyone? Provider hesitancy should not necessarily exclude high-risk men from participating in AS. Rather, clinicians should employ shared decision-making, sound clinical judgment, and stringent follow-up in order to effectively counsel AS candidates and optimize AS-related outcomes in "high-risk" individuals.

Keywords: Active surveillance; High-risk men; Low-risk; Prostate cancer.

Publication types

  • Review

MeSH terms

  • Feasibility Studies
  • Humans
  • Male
  • Prostate-Specific Antigen*
  • Prostatic Neoplasms* / diagnosis
  • Prostatic Neoplasms* / therapy
  • Risk Assessment / methods
  • Watchful Waiting

Substances

  • Prostate-Specific Antigen